ImmunityBio (IBRX) Share-based Compensation (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Share-based Compensation data on file, last reported at $16.4 million in Q1 2026.

• On a quarterly basis, Share-based Compensation changed N/A year-over-year to $16.4 million in Q1 2026; TTM through Mar 2026 was $22.3 million, a 107.16% increase from a year earlier, with the FY2025 full-year figure at $5.9 million, down 59.63% from the prior year.
• Share-based Compensation for Q1 2026 stood at $16.4 million, up from -$22.2 million in the prior quarter.
• Over the last five years, Share-based Compensation for IBRX reached as high as $26.5 million in Q3 2025 and fell as low as -$22.2 million in Q4 2025.
• Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $2.7 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 2824.19% in 2023 and fell as far as 69840.0% in 2023.
• Year by year, Share-based Compensation stood at -$10.0 million in 2022, then soared by 185.41% to $8.6 million in 2023, then rose by 16.16% to $10.0 million in 2024, then tumbled by 322.47% to -$22.2 million in 2025, then surged by 173.91% to $16.4 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $16.4 million in Q1 2026, -$22.2 million in Q4 2025, and $26.5 million in Q3 2025.